Press release 📈 Stocks 🌍 United States

MetaVia Completes Final Phase 1 Study Visit for DA-1726 Liver Drug

MetaVia has finished the final visit for its 24-week Phase 1 trial of DA-1726, setting the stage for full data in Q1 2027 and a planned Phase 2 study in the second half of 2027.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: MTVA ↑ 4/10 (60% confidence).

📊 Affected Assets (1)

MTVA
Bullish 🤖 60%
📆 Mid-term 🌍 US · Explicit

MetaVia completes the last patient visit in the 24-week Phase 1 Part 3A study of DA-1726, having extended dosing from 16 to 24 weeks at 48 mg weekly. The release repeats hard interim figures: a statistically significant 68.1% placebo-adjusted liver fat reduction and 13.5% placebo-adjusted weight loss at Day 109. These are previously reported results, so today's news is largely a milestone rather than fresh data; the real catalysts are full Parts 3A/3B data in Q1 2027 and a Phase 2 start in H2 2027.

Catalysts
  • ▲ Completion of final study visit in extended 24-week Phase 1 Part 3A on Nov. 17, 2026
  • ▲ Full data from Parts 3A and 3B expected in Q1 2027
Risk Factors
  • ▼ The 68.1% and 13.5% efficacy figures are previously reported interim data, not new today
  • ▼ Preliminary safety and tolerability observations are not the full dataset

🧭 Full analysis of these assets

🎯 Key Takeaways

  • MetaVia completed the final patient visit for the extended 24-week Phase 1 Part 3A study of DA-1726 on Nov. 17, 2026.
  • Interim data for DA-1726 showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss at Day 109.
  • Full data from Phase 1 Parts 3A and 3B is scheduled for release in the first quarter of 2027.
  • The company plans to initiate a 48-week, non-biopsy Phase 2 study in up to 150 patients with MetALD and ALD in the second half of 2027.

📝 Executive Summary

MetaVia Inc. announced the completion of the final patient visit in its extended 24-week Phase 1 Part 3A clinical trial for DA-1726. The company previously reported positive interim results for the drug, including a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss. Full data from the study is expected in the first quarter of 2027, with a Phase 2 trial for MetALD and ALD planned for the second half of 2027.

❓ FAQ

Why is this announcement only moderately positive if the drug data look strong?

The headline efficacy numbers (68.1% liver fat reduction, 13.5% weight loss) were already reported in the interim analysis. Today's news is that the last patient completed the extended 24-week visit, which clears the way for full data in Q1 2027 rather than adding new figures.

When is the next major catalyst for MetaVia?

Full data from Parts 3A and 3B of the Phase 1 study are expected in the first quarter of 2027, with a Phase 2 study in MetALD and ALD planned to start in the second half of 2027.